155 related articles for article (PubMed ID: 17688389)
1. Signal detection methodologies to support effective safety management.
van Manen RP; Fram D; DuMouchel W
Expert Opin Drug Saf; 2007 Jul; 6(4):451-64. PubMed ID: 17688389
[TBL] [Abstract][Full Text] [Related]
2. Drug Safety Evaluation in China.
Li L; Yin J
Curr Allergy Asthma Rep; 2019 Jul; 19(9):39. PubMed ID: 31321555
[TBL] [Abstract][Full Text] [Related]
3. Good pharmacovigilance practices: technology enabled.
Nelson RC; Palsulich B; Gogolak V
Drug Saf; 2002; 25(6):407-14. PubMed ID: 12071777
[TBL] [Abstract][Full Text] [Related]
4. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA.
Weaver J; Willy M; Avigan M
AAPS J; 2008; 10(1):35-41. PubMed ID: 18446503
[TBL] [Abstract][Full Text] [Related]
5. Performance assessment of the Thai National Center for Pharmacovigilance.
Kaewpanukrungsi W; Anantachoti P
Int J Risk Saf Med; 2015; 27(4):225-37. PubMed ID: 26756896
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance.
Harinstein L; Kalra D; Kortepeter CM; Muñoz MA; Wu E; Dal Pan GJ
Drug Saf; 2019 May; 42(5):649-655. PubMed ID: 30569267
[TBL] [Abstract][Full Text] [Related]
7. The quantification of drug risks in practice.
Lee D; Bergman U
WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852
[No Abstract] [Full Text] [Related]
8. Social Media Listening for Routine Post-Marketing Safety Surveillance.
Powell GE; Seifert HA; Reblin T; Burstein PJ; Blowers J; Menius JA; Painter JL; Thomas M; Pierce CE; Rodriguez HW; Brownstein JS; Freifeld CC; Bell HG; Dasgupta N
Drug Saf; 2016 May; 39(5):443-54. PubMed ID: 26798054
[TBL] [Abstract][Full Text] [Related]
9. FDA post-marketing safety decisions.
Klein DF
J Clin Psychiatry; 2006 Aug; 67(8):1305-6. PubMed ID: 16965212
[No Abstract] [Full Text] [Related]
10. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
Goldman SA
Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
[No Abstract] [Full Text] [Related]
11. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
[TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance in clinical dentistry: overlooked or axiomatic?
Carnelio S; Khan SA; Rodrigues G
Gen Dent; 2011; 59(1):24-8; quiz 29-30, 80. PubMed ID: 21613036
[TBL] [Abstract][Full Text] [Related]
13. Evolving paradigms in pharmacovigilance.
Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
[TBL] [Abstract][Full Text] [Related]
14. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues.
Bergvall T; Norén GN; Lindquist M
Drug Saf; 2014 Jan; 37(1):65-77. PubMed ID: 24343765
[TBL] [Abstract][Full Text] [Related]
15. [The new pharmacovigilance legislation in practice].
Broekmans AW; Mol PG
Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
[TBL] [Abstract][Full Text] [Related]
16. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity.
Maro JC; Brown JS; Dal Pan GJ; Kulldorff M
Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):839-48. PubMed ID: 24700557
[TBL] [Abstract][Full Text] [Related]
17. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
18. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
19. The Erice Manifesto: for global reform of the safety of medicines in patient care.
Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
[TBL] [Abstract][Full Text] [Related]
20. Innovations for the future of pharmacovigilance.
Almenoff JS
Drug Saf; 2007; 30(7):631-3. PubMed ID: 17604419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
